Basha Riyaz, Sabnis Nirupama, Heym Kenneth, Bowman W Paul, Lacko Andras G
Department of Pediatrics, University of North Texas Health Science Center , Fort Worth, TX , USA ; Institute for Cancer Research, University of North Texas Health Science Center , Fort Worth, TX , USA.
Departments of Integrated Physiology and Pediatrics, University of North Texas Health Science Center , Fort Worth, TX , USA.
Front Oncol. 2014 May 13;4:101. doi: 10.3389/fonc.2014.00101. eCollection 2014.
The two major forms of leukemia, acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), account for about one-third of the malignancies diagnosed in children. Despite the marked successes in ALL and AML treatment, concerns remain regarding the occurrence of resistant disease in subsets of patients, the residual effects of therapy that often persist for decades beyond the cessation of treatment. Therefore, new approaches are needed to reduce or to avoid off target toxicities, associated with chemotherapy and their long-term residual effects. Recently, nanotechnology has been employed to enhance cancer therapy, via improving the bioavailability and therapeutic efficacy of anti-cancer agents. While in the last several years, numerous review articles appeared detailing the size, composition, assembly, and performance evaluation of different types of drug carrying nanoparticles, the description and evaluation of lipoprotein-based drug carriers have been conspicuously absent from most of these major reviews. The current review focuses on such information regarding nanoparticles with an emphasis on high density lipoprotein-based drug delivery systems to examine their potential role(s) in the enhanced treatment of children with leukemia.
白血病的两种主要形式，即急性淋巴细胞白血病（ALL）和急性髓细胞白血病（AML），约占儿童确诊恶性肿瘤的三分之一。尽管在ALL和AML治疗方面取得了显著成功，但对于部分患者出现耐药性疾病以及治疗的残留影响（这些影响在治疗停止后往往会持续数十年）仍存在担忧。因此，需要新的方法来减少或避免与化疗及其长期残留影响相关的脱靶毒性。最近，纳米技术已被用于通过提高抗癌药物的生物利用度和治疗效果来增强癌症治疗。虽然在过去几年中出现了大量综述文章，详细介绍了不同类型载药纳米颗粒的尺寸、组成、组装和性能评估，但大多数这些主要综述中明显缺乏对基于脂蛋白的药物载体（LBDCs）的描述和评估。本综述重点关注有关纳米颗粒的此类信息，尤其着重于基于高密度脂蛋白的药物递送系统，以研究它们在增强儿童白血病治疗中的潜在作用。
